via Neuroscience News
New approach using multiple microRNA ‘hitchhikers’ to weaken cancer cells in advance of standard therapy shows promise in preclinical models
In cancer therapeutics research, microRNAs–tiny strings of nucleotides that get churned out inside cells–have been a source of both excitement and disappointment. While preclinical studies have found that microRNAs play an important role in cancer and other diseases, two cancer clinical trials to date using microRNAs showed little response and significant toxicity. A team of investigators at Brigham and Women’s Hospital and Harvard Medical School has begun looking at these molecules in an entirely new way. Rather than modulating just one, they grouped together multiple microRNAs that naturally occur in the brain by encoding them in a small, artificial gene, and co-opted cancer cells’ molecular machinery to overproduce these groups of molecules to weaken the cells. Their approach has shown promising results in preclinical models, increasing survival in a murine model of glioblastoma by five-fold when combined with chemotherapy. The team’s results are published in Nature Communications.
“I like to think of it as hitchhiking. Cancer cells have a built-in system to produce and recognize microRNAs and we’re getting them to ‘pick up’ our sequence–which encodes multiple microRNAs–and start making more copies of them. The cellular machinery is running, and our sequence is along for the ride,” said corresponding author Pierpaolo Peruzzi, MD, PhD, an attending clinical neurosurgeon in the Department of Neurosurgery, as well as a principal investigator in the Harvey Cushing Neuro-Oncology Laboratories at the Brigham.
Peruzzi and colleagues, including lead author Vivek Bhaskaran, PhD, a postdoctoral fellow in the Department of Neurosurgery, set out to find groups of microRNAs responsible for regulating complex pathways. Using bioinformatic analysis, the team focused on a group of three microRNAs–miR-124, miR-128 and miR-137–which work as a team in properly developing neurons but are lost during the formation of brain cancer. The team found that several of these microRNAs’ targets included proteins involved in glioblastoma recurrence and resistance to conventional therapies.
The research team tested its findings using multiple cancer cell lines, including glioblastoma as well as non-glioblastoma cell lines. In addition, investigators tested the effectiveness of modulating all three microRNAs at once in a mouse model of intracranial tumors. The team reported a significant survival benefit. Without treatment, the mouse model survived 12 days post-tumor implantation, and chemotherapy extended this to a median of 18 days. But when chemotherapy and the multi-microRNA treatment were combined, survival was extended to a median of 48.5 days.
“These results are very encouraging and may provide a realistic treatment option,” said Bhaskaran.
Peruzzi notes that the multi-microRNA strategy weakens tumor cells but does not directly kill them. “While it seems a bit counterintuitive, this is actually an advantage, since by remaining alive, although severely impaired, cancer cells continue to produce microRNAs which eventually flood the entire tumor.” Indeed, the authors showed that these artificial microRNAs spread through the tumor through tiny vesicles and leave it more vulnerable to chemotherapy.
“We’re coaxing the tumor to produce its own poison, and then we hit it for good with chemotherapy or radiation,” said Peruzzi. “And we’re optimistic that in a relatively short time we can advance this approach to the clinic. A further refined and even more potent version of this concept is already in the pipeline.”
There are currently clinical trials underway at the Brigham leveraging viral vectors and gene therapy approaches for treating glioblastoma (both primary and recurrent). Peruzzi and colleagues are working to further refine their microRNA approach with the goal of using viral vectors to deliver these microRNAs to tumors in brain cancer patients.
Learn more:Â The hitchhiker’s guide to defeating glioblastoma
The Latest on: Glioblastoma
via Google News
The Latest on: Glioblastoma
- Biomarkers found that could be drug targets against a deadly form of brain canceron June 22, 2022 at 12:02 pm
Currently, the drug most often used to treat glioblastoma, temozolomide, is uniquely able to cross the blood/brain barrier to attack the tumor but resistance develops rapidly, and many patients do ...
- Winner of notable research award discusses inclusion, diversity in laboratory environmentson June 22, 2022 at 9:00 am
Sara Ranjbar, PhD, winner of the Mayo Clinic’s 2021 Edward C. Kendall Alumni Award for Meritorious Research, has always known she wanted a job that would enable her to help patients and be of service ...
- VBI Vaccines Receives U.S. FDA Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastomaon June 22, 2022 at 5:00 am
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the U.S. Food and Drug ...
- Midatech Pharma PLC Announces MTX110 Development for the Treatment of Gliomaon June 20, 2022 at 11:00 pm
Orphan Designation Granted by EMA to MTX110 Development for the Treatment of GliomaABINGDON, NR / ACCESSWIRE / June 21, 2022 / Midatech Pharma PLC (AIM:MTPH.L)(Nasdaq:MTP), an R&D biotechnology ...
- A new, highly effective light therapy can target and kill cancer cellson June 20, 2022 at 1:50 pm
The light-activated therapy makes cancer cells glow in the dark, helping surgeons identify the tumors and effectively get rid of them, showing great promise.
- Scientists harness light therapy to target and kill cancer cells in world firston June 17, 2022 at 6:46 am
In a world-first trial in mice with glioblastoma, one of the most common and aggressive types of brain cancer, scans revealed the novel treatment lit up even the tiniest cancer cells to help ...
- CBD And CBG Show Promising Results In Treating Glioblastoma Brain Tumorson June 16, 2022 at 8:07 am
MGC Pharmaceuticals , a publicly-traded cannabis company, recently finalized pre-clinical trial research of cannabinoids as a potential treatment for glioblastoma, an aggressive brain ...
- Mom battling brain cancer launches bucket list challenge with support of NBA superstarson June 16, 2022 at 8:00 am
For any Boston Celtics fan, the chance to sit inside the TD Garden during an NBA finals game is a coveted opportunity. But for Heather Walker, a return to the court feels like a p ...
- 3CBD And CBG Show Promising Results In Treating Glioblastoma Brain Tumorson June 16, 2022 at 3:19 am
MGC Pharmaceuticals MXC, a publicly-traded cannabis company, recently finalized pre-clinical trial research of cannabinoids as a potential treatment for glioblastoma, an aggressive brain cancer.
- BRIEF-Mgc Pharmaceuticals Announces Successful Glioblastoma Pre-Clinical Trial Resultson June 16, 2022 at 12:22 am
MGC-STUDY UNDERTAKEN ON 30 BIOPSY SAMPLES FROM 18 PATIENTS,SOUGHT TO DETERMINE OPTIMAL FORMULATION FOR TREATMENT OF GLIOBLASTOMA * MGC- DEMONSTRATED PROPRIETARY FORMULATIONS CYTOTOXIC TO ...
via Bing News